- LATEST
- WEBSTORY
- TRENDING
BUSINESS
Ranbaxy ends patent dispute with GlaxHimangshu Watts
Ranbaxy Laboratories Ltd has won 180 days of exclusive rights to sell a generic form of GlaxoSmithKline’s Valtrex in the United States.
Updated : Sep 15, 2017, 01:05 AM IST
TRENDING NOW
)
AR Rahman, Saira Banu's daughter Raheema opens up on parents' divorce being linked to Mohini Dey: 'Always remember...'
)
Riddhima Kapoor Sahni reveals Rishi Kapoor's last two wishes: 'He wanted to see Ranbir Kapoor getting...'
)
Sana Khan, former Bigg Boss contestant, actress announces 2nd pregnancy with Anas Saiyad: 'Only Allah has power to..'
)
'Good to be back': After breaking up with Malaika Arora, Arjun Kapoor reunites with his 'partner-in-crime after ages'
)
'Your dance lightens up...': Little girl's dance on 'Tere Bina na Guzara E' steals hearts online, WATCH viral video
)
This Pakistani Influencer's private video leaked online, days after Minahil Malik and Insha Rehman's clips
)
32-year-old superstar forcibly kissed 15-year-old co-star; left her traumatised, crying; later laughed about it saying..
)
Amid Aishwarya Rai-Abhishek Bachchan divorce rumours, Jaya Bachchan says 'not my daughter' in viral video
)
Telecom rules to change from January 1, Mukesh Ambani's Jio, Airtel, Vi, BSNL will be affected due to...
)
Mukesh Ambani's SUPERHIT plan for Jio users, offers unlimited 5G access for 1 year for just Rs...
)
AR Rahman's bassist Mohini Dey reacts to her split linked with composer's divorce with Saira Banu: 'I know exactly..'
)
Gandii Baat, XXX actress Aabha Paul sets Instagram on fire with hot photos
)
Good news for Delhi-NCR residents, travel time from Noida to Gurugram to be reduced as new train service will...
)
Meet Mathira Khan, Pakistani influencer whose private video leaked after Minahil Malik, Imsha Rehman
)
Meet man who studied from IIT Delhi, IIM Calcutta, later resigned high-paying job in MNC, took Sanyas, now he is...
MUMBAI: Ranbaxy Laboratories Ltd has won 180 days of exclusive rights to sell a generic form of GlaxoSmithKline’s Valtrex in the United States after resolving a patent row, sending its shares up as much as 10% on Thursday.
The country’s biggest drug maker by sales expected strong gains after resolving the patent litigation with Glaxo, and also expected to win similar exclusive rights for at least one drug every year for the next four years, chief executive officer Malvinder Singh said.
“There is a very big upside. It is a $1.3 billion product today and growing at the rate of 20%,” Singh said of Valtrex, which is used to treat herpes infections.
Ranbaxy received approval from the U.S. Food and Drug Administration in February for valacyclovir hydrochloride, the active ingredient of Valtrex. It will launch the drug in the U.S. market in late 2009.
Market exclusivity, given to the drug maker that is the first to file a challenge to a U.S. patent, gives lucrative margins to the generics firm and has boosted earnings of firms like Ranbaxy and rival Dr Reddy’s Laboratories.
Singh said Ranbaxy, which has challenged 20 patents in the United States, had a very strong position in some litigation and was open to resolving disputes the way it did with Glaxo. “I’m certainly open to settlement as a way forward. We need to identify ways to monetise these opportunities,” Singh said by telephone from New Delhi.
He also said the company was confident it would exceed its outlook for 20% revenue growth in 2007.
“This year, clearly we are exceeding that guidance,” he said. Ranbaxy’s shares closed 9.5% higher at Rs 373.4 after rising as much as 10.1% during trade. It was their biggest single-day gain in over a year.
Singh said he was not perturbed by a Spanish court’s ruling on Wednesday that upheld Pfizer Inc’s patent covering an active ingredient in its cholesterol-fighter Lipitor.
“That’s a very small basic thing,” he said, adding the company would appeal against the ruling.
